AVI Biopharma (NASDAQ: [[ticker:AVII]]), the Portland, OR-based developer of RNA interference drugs, said today it has gotten the second of two patents needed for its drug that treats infections with Ebola Zaire virus. The patents cover composition of matter and methods for treating Ebola with a range of compounds, and they expire Oct. 31, 2025, AVI said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
